Skip to main content
S&P 5007,676.77+0.70%DOW52,361.58+0.28%NASDAQ26,169.38+0.82%BTC$79,628.00-0.95%ETH$2,308.01-0.94%GOLD$4,009.90-0.71%OIL$101.82+0.06%
Smart Investors Daily
SID Premium
EC

NASDAQ · ECOR

electroCore, Inc.

Healthcare · Medical - Devices

$7.44

Up+$0.39 (+5.53%)

Updated Oct 27, 2026, 10:06 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
39.09M
P/E ratio
-3.07
Dividend yield
0.00%
52-week range
$4.41 – $12.70
Volume
71.32K
Avg. volume
53.04K

Price performance · ECOR

ECOR price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 26, 2026

ECOR closed at $7.44 after 21 trading sessions, down 32.55% for the selected period.

Last close
$7.44
Period change
-32.55%
Period low
$7.05
Period high
$11.03
Daily close
View OHLC price history
ECOR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 26, 2026$7.07$7.57$7.07$7.4471.32K
Oct 23, 2026$7.25$7.50$7.00$7.05131.2K
Oct 22, 2026$7.13$7.7199$7.13$7.4138.07K
Oct 21, 2026$7.9473$7.9473$7.27$7.3553.14K
Oct 20, 2026$7.52$8.00$7.40$7.4955.21K
Oct 19, 2026$7.82$8.1755$7.40$7.6370.69K
Oct 16, 2026$8.29$8.42$7.35$7.85141.38K
Oct 15, 2026$8.13$8.4985$7.87$8.3593.42K
Oct 14, 2026$8.26$8.57$8.02$8.20118.72K
Oct 13, 2026$9.12$9.3877$8.15$8.39184.74K
Oct 12, 2026$9.78$9.78$8.97$9.2855.29K
Oct 9, 2026$9.37$9.79$9.37$9.6644.57K
Oct 8, 2026$9.65$10.0499$9.42$9.5152.89K
Oct 7, 2026$9.8201$10.2299$9.685$9.7248.63K
Oct 6, 2026$10.25$10.4499$9.89$9.9239.72K
Oct 5, 2026$10.14$10.2499$9.90$10.1331.99K
Oct 2, 2026$10.47$11.02$9.92$10.14122.25K
Oct 1, 2026$11.00$11.0795$10.00$10.31597.54K
Sep 30, 2026$10.725$11.0928$10.65$10.8249.2K
Sep 29, 2026$11.16$11.3333$10.52$10.8863.27K
Sep 28, 2026$11.00$11.28$10.7301$11.03114.28K

Latest ECOR news

The latest Smart Investors Daily articles mentioning ECOR.

Stock researchCompany · Overview

ECOR research

Overview

Company profile and research snapshot.

Company profile

electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ECOR recent ratings
DateFirmRatingTarget
Jan 26, 2026HC Wainwright & Co.Buy—
Mar 13, 2025Ladenburg ThalmannBuy—
Mar 13, 2025HC Wainwright & Co.Buy—
Dec 18, 2024HC Wainwright & Co.Buy—
Mar 14, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

electroCore to Present at Planet MicroCap Toronto 2026 powered by MicroCapClub

ROCKAWAY, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be presenting at Planet MicroCap Toronto 2026 Powered by MicroCapClub being held at the Arcadian Court & Loft. Joshua Lev, Co-CEO, President and CFO, will deliver a presentation and host one-on-one investor meetings throughout the conference. Conference Details: Dates: October 27-29Company Presentation: Wednesday, October

Benzinga · Sep 18, 2026

Full Transcript: electroCore Q2 2026 Earnings Call

electroCore (NASDAQ:ECOR) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By